Core Insights - Branded Legacy, Inc. has formed a strategic partnership with Dr. Eran Bendavid from Stanford University to enhance addiction research through evidence synthesis and policy analysis [1][2] - The collaboration aims to leverage advanced AI-powered systematic review platforms to process scientific literature rapidly, ensuring that Branded Legacy's innovations are grounded in the latest medical evidence [2][3] - The partnership focuses on the development of intranasal naloxone, addressing the urgent need for effective solutions in the ongoing opioid crisis, particularly driven by fentanyl [2][4] Company Developments - The acquisition of Bio-Legacy Evaluative Group and the partnership with McMaster University, along with the collaboration with Stanford, positions Branded Legacy as a leader in biotech innovation for addiction treatment [4] - The naloxone market is projected to grow from $371 million in 2022 to over $1.16 billion by 2032, with a compound annual growth rate (CAGR) of approximately 11.9% [4] - Branded Legacy's patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment, while also enabling nasal delivery of vaccines and other medications [5]

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for meetings wi ...

Group 1 - Hawkeye Invest AS, controlled by Øystein Barmen, has purchased 240,000 shares in PCI Biotech Holding ASA [1] - Following the transaction, Hawkeye Invest AS now owns 2,000,000 shares, representing 5.36% of the total shares in PCI Biotech Holding ASA [1]

Summary of WuXi Biologics Cayman Inc Conference Call Company Overview - **Company**: WuXi Biologics Cayman Inc - **Industry**: Biopharmaceuticals - **Date of Call**: August 21, 2025 Key Highlights 1. **Financial Performance**: - 1H25 revenue increased by 16% YoY, and earnings rose by 55% YoY. Excluding WuXi XDC, revenue growth was approximately 9% YoY [1][2] - Full-year revenue growth guidance revised from 12-15% to 14-16%, with WuXi XDC's guidance raised from 35% to over 45% [1] 2. **Project Acquisition**: - Acquired 86 new integrated projects in 1H25, totaling 864 projects, with over half from US biotech companies. Approximately 50 projects are eligible for royalties, and 2-3 have blockbuster potential [2] - First-in-class drug candidates account for about 40% (338 programs) of the total projects [2] 3. **Market Performance**: - North America was the strongest market, with revenue up 20% YoY, driven by pre-IND and expanded late-stage/CMO contracts. Out-licensing of Chinese drug assets to American biotechs was significant [3] - Revenue in China decreased by 9% YoY due to changes in contract-signing parties for out-licensed assets [3] 4. **Backlogs**: - Service backlog reached US$11.4 billion (+13.5% YoY) and milestone backlog at US$9.0 billion (+26.6% YoY, non-probability adjusted). The service backlog was supported by all development stages, while milestone backlog was driven by research phase projects [4] 5. **Clinical Trials**: - 67 projects in Phase 3 trials and 24 at commercial stage contributed 43% of total revenue in 1H25, with a goal of 50% by 2030 [5] 6. **Bioreactor Capacity**: - Current bioreactor capacity is approximately 300,000L, with plans to reach ~491,000L in a few years. The supply chain is diversified across multiple countries to mitigate geopolitical risks [6] 7. **High-Concentration Biologics**: - WuXiHigh 2.0 has achieved titers of up to 230mg/ml, with about 20% of FDA-approved biologics and ~40% in the pipeline being high-concentration [7] 8. **Investor Sentiment**: - Investor concerns regarding geopolitics have lessened, as recent amendments to the Biosecure Act do not target Chinese companies in the biotech sector [11] Financial Metrics - **Market Capitalization**: HK$129,436 million - **Current Share Price**: HK$30.62 - **Price Target**: HK$35.00 (14% upside) [8] - **EPS Estimates**: - 2025: Rmb0.93 - 2026: Rmb1.15 - 2027: Rmb1.40 [8] Risks and Opportunities - **Upside Risks**: - Faster pharmaceutical market growth and increased outsourcing of R&D globally [14] - **Downside Risks**: - Potential slowdown in biologics programs and geopolitical risks [14] Conclusion WuXi Biologics is positioned for growth with strong revenue performance, a robust project pipeline, and strategic market positioning, particularly in North America. However, challenges in the Chinese market and geopolitical factors remain critical considerations for investors.

Core Viewpoint - Calidi Biotherapeutics, Inc. has successfully closed a public offering, raising gross proceeds of $6.9 million, which includes the full exercise of the underwriters' over-allotment option [1][2]. Group 1: Offering Details - The company sold a total of 1,922,764 common stock units, each consisting of one share of common stock and one Series I warrant, and 1,528,000 pre-funded warrant units, each consisting of one pre-funded warrant and one Series I warrant [2]. - The price per Common Stock Unit was set at $2.00, while the Pre-Funded Unit was priced at $1.999 [2]. - The Series I warrants have an exercise price of $2.00 per share, are exercisable upon issuance, and will expire five years from issuance [2]. Group 2: Management and Regulatory Information - Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for the offering, with Laidlaw & Company (U.K.) Ltd. acting as a co-manager [3]. - The securities were offered under a registration statement on Form S-1, which was declared effective by the SEC on August 20, 2025 [4]. Group 3: Company Overview - Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing targeted therapies that can deliver genetic medicines to distal disease sites [6]. - The company's proprietary Redtail platform utilizes an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, aiming to enhance the effectiveness of virotherapy [6]. - The lead candidate from the Redtail platform is currently in IND-enabling studies and targets non-small cell lung cancer, ovarian cancer, and other tumor types with significant unmet medical needs [7].

Group 1 - Iovance Biotherapeutics has taken initial steps to rebuild confidence in the launch of Amtagvi (lifileucel) [1] - The company's financial situation regarding cash resources compared to cash burn remains questionable [1] - A previous analysis rated Iovance Biotherapeutics as a hold, indicating cautious optimism [1]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 50 points on Thursday.The Dow traded down 0.62% to 44,660.91 while the NASDAQ fell 0.74% to 21,016.48. The S&P 500 also fell, dropping, 0.66% to 6,353.29.Check This Out: How To Earn $500 A Month From Intuit Stock Ahead Of Q4 EarningsLeading and Lagging SectorsHealth care shares jumped by 0.7% on Thursday.In trading on Thursday, consumer staples stocks fell by 0.9%.Top HeadlineShares of Walmart Inc. WMT fell 4% on Thursd ...

Core Viewpoint - Krystal Biotech, Inc. is advancing the development of KB707, a redosable immunotherapy targeting non-small cell lung cancer (NSCLC), with promising early efficacy data leading to an End of Phase 2 meeting with the FDA to discuss registration pathways [1][2][3] Group 1: Development Plans and Efficacy - The company has observed a 36% objective response rate in heavily pre-treated NSCLC patients as of April 15, 2025, with no Grade 4 or 5 adverse events reported, indicating a favorable safety profile [3] - Enrollment is ongoing in the KYANITE-1 study, a Phase 1/2 trial evaluating inhaled KB707 in patients with locally advanced or metastatic lung tumors [4] - The company has paused enrollment in the OPAL-1 study, which evaluates intratumoral KB707, to prioritize inhaled KB707, while continuing to monitor patients in OPAL-1 [5] Group 2: Company Overview - Krystal Biotech is a commercial-stage biotechnology company focused on genetic medicines for diseases with high unmet medical needs, with its first product, VYJUVEK, being the first redosable gene therapy approved in multiple regions [6]

Core Insights - Shattuck Labs, Inc. is developing SL-325, a potentially first-in-class DR3 antagonist antibody aimed at treating Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases [1][5] - The company plans to dose the first participant in its Phase 1 clinical trial in healthy volunteers in Q3 2025, with enrollment expected to be completed by Q2 2026 [2][4] - Current cash and cash equivalents, along with anticipated proceeds of up to $103 million from a recent private placement, are expected to fund operations into 2029 [1] Company Overview - Shattuck Labs, Inc. specializes in developing treatments for autoimmune and inflammatory diseases, focusing on novel therapeutics targeting TNF superfamily receptors [5] - The company has offices in Austin, Texas, and Durham, North Carolina [5] Clinical Development - SL-325 is designed to achieve a complete and durable blockade of the DR3/TL1A pathway, with preclinical studies showing high-affinity binding and superior activity compared to TL1A antibodies [4] - The Phase 1 clinical trial will evaluate safety, tolerability, and pharmacokinetics through a randomized, double-blind, placebo-controlled design [2]